Please login to the form below

Not currently logged in
Email:
Password:

Perjeta

This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.

AZ’s bet on Daiichi’s rival to Kadcyla pays off

AZ’s bet on Daiichi’s rival to Kadcyla pays off

drug trio alongside Herceptin (trastuzumab) and Perjeta (pertuzumab).

Latest news

More from news
Approximately 17 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics